A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

New research suggests that Americans' risk for developing dementia over a lifetime may be higher than previously thought.

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

INR:8913. go fishing game Confirmed! The state ordered all cities to stockpile medical equipment (list attached) New company accelerating the development of multi ...

INR:5146. maharashtra state kabaddi association A 100 billion market change! CRO may fully undertake the "drug preparation innovation" busin ...

Bulk elk meat for sale R&D Daily丨Biogen submits marketing application for Alzheimer's disease treatment drug aducanumab Academician Chen Wei: T ...

Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 “Bringing Alzheimer’s disease treatment options to the ...

The Schmitts agreed to receive a monthly infusion of Aducanumab, which is based on the same principle as Leqembi: It is an antibody, in this case from the U.S. biotechnology company Biogen.

Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said. Alzheimer's charities say they are disappointed by the decision because thousands of people ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...